Carregant...
Amuvatinib has cytotoxic effects against NRAS- but not BRAF-mutant melanoma
Effective targeted therapy strategies are still lacking for the 15–20% of melanoma patients whose melanomas are driven by oncogenic NRAS. We here report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα and Rad51. An analysis of BRAF- and NRAS-m...
Guardat en:
| Publicat a: | Melanoma Res |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4384823/ https://ncbi.nlm.nih.gov/pubmed/24950457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000103 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|